|
Oct 3
|
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients
|
|
Aug 26
|
Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested
|
|
Jul 31
|
Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma
|
|
Feb 7
|
Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
|
|
Jan 16
|
Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference
|
|
Dec 5
|
Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now
|
|
Oct 16
|
Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
|
|
Aug 9
|
Q2 2023 Theriva Biologics Inc Earnings Call
|
|
Aug 8
|
Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results
|